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Objective: The aim of the trial was to assess the efﬁcacy of chondroitin sulphate (CS) on symptomatic
knee osteoarthritis (OA) associated to psoriasis.
Methods: In this randomized, double-blind, placebo (PBO)-controlled clinical trial 129 patients with
symptomatic knee OA and concomitant psoriasis were randomized into two groups receiving 800 mg
daily of CS or PBO for 3 months. The primary efﬁcacy outcome for knee OA was the Huskisson’s visual
analogue scale (VAS) and for psoriasis was the Psoriasis Area and Severity Index (PASI). Additionally,
other secondary efﬁcacy criteria for both conditions were assessed.
Results: After 3 months of treatment, CS was more effective than PBO, relieving pain VAS (CS 26.9 24.8
vs PBO 14.23 20.8 mm, P< 0.01), decreasing the Lequesne index (CS 4.8 3.4 vs PBO 3.3 3.5,
P< 0.05) and reducing the number of patients using acetaminophen as rescue medication (CS 43% vs PBO
64%, P< 0.05). Regarding PASI, Overall Lesion Severity Scale and Physician’s Global Assessment of Change
no statistically signiﬁcant changes were detected in front of PBO. However, CS improved plantar psoriasis
compared to PBO (CS 87% vs PBO 27%, P< 0.05). Quality of life improved signiﬁcantly in CS-treated patients
according to the Short Form-36 health survey and the Dermatology Life Quality Index (DLQI). CS tolerability
was excellent. Adverse events were infrequent and evenly distributed among groups. The incidence of
psoriatic ﬂares did not increase after treatments.
Conclusions: This study conﬁrms the efﬁcacy and safety of CS as a symptomatic slow-acting drug in
patients with knee OA and shows that CS improves plantar psoriasis. The use of CS could represent
a special beneﬁt in patients with both pathologies since non-steroidal anti-inﬂammatory drugs have
been reported to induce or exacerbate psoriasis.
FDA Clinical Trials Government Identiﬁer: NCT00669123.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is a common, progressive condition, which is
associated with severe pain, functional disability and impairment
of health-related quality of life, causing a signiﬁcant social and
economic burden1. OA of the hip or knee affects the majority ofngrid Möller, Instituto Poal de
, Spain. Tel: 34-93-4340192.
).
s Research Society International. Pindividuals over 60 years of age in developed countries2. Irrevers-
ible damage to articular cartilage, osteophyte formation, alterations
in the subchondral bone and synovial inﬂammation are charac-
teristic features of the disease3.
Chondroitin sulphate (CS) is a glycosaminoglycan, which is
a major component of the extracellular matrix of many connective
tissues including cartilage, bone, skin, ligaments and tendons4. CS
has been classiﬁed as a symptomatic slow-acting drug in OA
(SYSADOA) and as a structure/disease modifying anti-OA drug
(S/DMOAD)5,6. Randomized placebo (PBO)-controlled clinical trials
in patients with knee OA have shown that CS reduces pain,ublished by Elsevier Ltd. All rights reserved.
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inﬂammatory drug (NSAID) or analgesic consumption7, has a carry-
over effect5, reduces joint swelling and effusion8, and is tolerated as
well as the PBO3,5,7,9e11. Moreover, CS prevents joint space nar-
rowing of the knee5,6,12 and ﬁngers13,14 more effectively than PBO.
The beneﬁcial effects of CS in patients with OA result from its
inmunomodulatory effects reducing NF-kB nuclear trans-
location15,16, from the stimulation of proteoglycan and hyaluronic
acid synthesis in chondrocytes, from the anti-inﬂammatory activity
and inhibition of proteolytic enzymes, of nitric oxide and other
substances that contribute to damage the cartilage matrix and
cause chondrocytes death. At the same time, CS has proven to have
a positive effect on some of the pathological processes involving the
synovial tissue and subchondral bone17.
The beneﬁcial effects elicited by CS in the treatment of OA, raise
the hypothesis that CS might be effective in other chronic inﬂam-
matory processes such as psoriasis inwhich a deregulation of NF-kB
plays an important role18.
It is interesting to note that in a clinical series of 11 patients with
knee OA and concomitant psoriasis, the use of CS as a symptomatic
treatment for knee OA resulted in a marked clinical and histological
improvement of the psoriatic lesions after 2 months of treat-
ment19,20. Taking into account these preliminary results, a double-
blind, PBO-controlled pilot clinical trial was designed to assess the
efﬁcacy and safety of CS in patients with symptomatic knee OA and
concomitant psoriasis.
Methods
Study design
A prospective, randomized, double-blind, PBO -controlled
multicentre study was designed to assess the efﬁcacy and safety of
CS 800 mg daily compared to PBO in patients with both OA of the
knee and concomitant plaque-type psoriasis. According to the
response observed in a former exploratory study19,20, the duration
of the treatment period was limited to 3 months.
The study comprised patients from Barcelona (Spain) who were
enrolled between October 2004 and February 2007 in two centres,
the Instituto Poal de Reumatología and the Hospital del Mar. The
study protocol was approved by the Ethical Review Board of
the participating centres andwas conducted in accordancewith the
principles of the Declaration of Helsinki and its amendments.
Written informed consent was obtained from all participants prior
to enrolment in the study.
Eligibility
Eligible patients were male and female subjects aged 40 years or
over, with OA of the knee as deﬁned by criteria of the American
CollegeofRheumatology21,withpain in theaffectedknee scoring30
ona continuous0e100 mmHuskisson’s visual analoguescale (VAS)22
and a conﬁrmatory knee X-ray diagnosis (KellgreneLawrence grades
IeIII)23 associated to cutaneousplaque-type psoriasiswith a Psoriasis
Area and Severity Index (PASI)24 score of5.
Key exclusion criteria were KellgreneLawrence grade IV,
VAS 30 due to pain of any cause in other sites, non-plaque-type
psoriasis forms, concurrent arthritic conditions that could confound
evaluation of the index joint, presence of any clinically signiﬁcant
cutaneous disease that may interfere with the assessment of lesions
during the study and presence of any medical condition judged by
the investigator to preclude the patient’s inclusion in the study. The
following medication washout periods before entering the study
were requested: 6 months for intra-articular hyaluronic acid, 3
months for intra-articular corticosteroids and SYSADOAs; 1 monthfor oral corticosteroids, 1 week for oral NSAIDs; 1 month for high-
potency topical corticosteroids, psoralen photochemotherapy and
systemic treatment for psoriasis; 2 weeks for ultraviolet and topical
treatment for psoriasis.
Treatment and patient evaluation
Study participants attended a screening visit, which included
medical history, physical examination, VAS and PASI scores, and
laboratory tests. Subjects were fully informed of the purpose of
the study and signed the informed consent. They were instructed
to discontinue or taper off gradually any systemic or topical
treatment for both pathologies in accordance with eligibility
criteria and were scheduled to return to the study centre for the
baseline/randomization visit (visit 0). At baseline, physical
examination was carried out, inclusion/exclusion criteria and
results of laboratory tests were reviewed, and the following
procedures were performed: assessment of knee pain using VAS
and functional disability by the Lequesne index, assessment
psoriasis severity by means of PASI and the Overall Lesion
Severity Scale (OLS), radiographic conﬁrmation of Kell-
greneLawrence grades IeIII, and punch biopsy collection.
Patients completed the Dermatology Life Quality Index (DLQI)25
and the Short Form-36 (SF-36) quality of life questionnaires.
Patients were instructed to collect data of daily consumption of
acetaminophen (500 mg) as rescue medication in the daily card.
Adverse events arising after signing the informed consent were
also documented.
All eligible participants were sequentially assigned by the
researchers to one of the twomasked products in a proportion of 1:1
per treatment group according to a pre-established computer-
generated global randomization list provided by the statisticians. The
randomization schedule was generated using the SAS PROC PLAN
programme(Release9.1.3 Service Pack2) forablock sizeof 2 anda1:1
ratio. Subjects were randomly assigned to receive daily either CS
800 mg (two capsules of 400 mgeach) (Condrosan, CS Bio-ActiveTM,
Bioibérica, S.A., Barcelona, Spain) or matched PBO capsules. Con-
drosan is aprescriptiondrugcontaininghighlypuriﬁedchondroitins
4 and 6 sulphate of bovine origin in a concentration not less than98%.
It has an average molecular weight of w15e16 kD and an intrinsic
viscosity of w0.02e0.06 m3/kg. This product has been approved as
a prescription treatment forOA inmany European countries. Subjects
were instructed totaketwocapsulesonceaday. Thestudymedication
was dispensed to subjects at the baseline visit to cover the 3-month
study period. Acetaminophen as rescuemedication for osteoarthritic
symptoms, syndet soapandmoisturizingbodymilk fordaily skincare
were also provided.
Assessments were performed at 30 days (visit 1), 60 days
(visit 2) and 90 days (visit 3, ﬁnal visit) after initiation of the
treatment. At follow-up visits, the same procedures as those
described for visit 0 were performed except for laboratory tests
and skin biopsy, which were only performed at the ﬁnal visit.
Changes in psoriatic lesions according to the Physician’s Global
Assessment of Change (PGA) method, as well as the patient’s and
investigator’s efﬁcacy and tolerability of treatment were also
assessed at each follow-up visit. The PGA categorizes the global
response to therapy of all clinical signs and symptoms of the
disease relative to baseline using all the available information for
the assessment including, registration of the different body areas
with psoriatic lesions and photographs taken at each visit under
standardized conditions. Treatment compliance by capsule count
and use of acetaminophen (500 mg, maximum allowed 3 g/day)
by inspection of daily cards was also checked at each visit. Non-
compliance was deﬁned as taking less than 75% of the prescribed
course of the study drug.
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anaesthesia at visits 0 and 3 from the same psoriatic plaque from
each subject. All biopsies were examined by two independent
pathologists who were unaware of the purpose of the study and
origin of the biopsy specimens. Quantitative, semiquantitative and
qualitative histological variables were assessed. Quantitative vari-
ables included the thickness of the epidermis, of the stratum cor-
neum and the thickness from stratum basale to the stratum corneum.
Semiquantitative variables were psoriasis activity and inﬂamma-
tion. Qualitative variables included orthokeratosis or parakeratosis,
presence of CD1aþ Langerhans cells, CD31þ endothelial cells,
CD4þ and CD8þ T lymphocytes, CD57þ natural killer cells, tripta-
seþmastocytes, and keratinocyte proliferation (Ki67 staining).
Efﬁcacy and safety parameters
The primary efﬁcacy endpoints were the decrease in pain
intensity assessed by VAS and the clinical improvement of psoriasis
determined by the PASI score at the end of treatment as compared
with baseline. Secondary efﬁcacy parameters included pain relief
and function improvement in the knee using the Lequesne algo-
functional index26, acetaminophen consumption, OLS score,
histopathological data, changes in psoriatic lesions according to
PGA, assessment of efﬁcacy by patients and investigators and
quality of life measured with SF-36 and DLQI.
Tolerability and safety parameters were the incidence and
severity of adverse events reported throughout the study, changes
in laboratory tests including complete blood cell count, biochemical
proﬁle and urinalysis and patient’s and investigator’s assessment of
tolerability.
Statistical analysis
The sample size calculation was determined to guarantee the
statistical power for the more restrictive of the two co-primary
endpoints, the PASI outcome. For that variable, a sample size of 60
evaluable patients provided an 80% power to detect a difference of 4
points assuming an SD of 7 points, with a two-sided alpha level of
0.025. Amultiplicity adjustmentwas applied by using the Bonferroni
correction for each of the two co-primary outcomes to maintain theEligible patients at
the screening v
n = 181
Patients randomise
Chondroitin sulfate, n = 64
ITT data set, n = 60
No data for at least one follow-up 
visit, n =4
PP data set, n = 58
Non-compliance, n = 2
Fig. 1. Flow-chart of the distroverall 5% type I error. Therefore, a total of 120 evaluable patients (60
per group) were required to analyze the co-primary endpoints of the
study and approximately 130 patients were predeﬁned to be
randomized considering a dropout rate of less than 10%.
The efﬁcacy analysis was performed for the intention-to-treat
(ITT) population deﬁned as all randomized patients who met the
inclusion/exclusion criteria, received the study medication and
fromwhich data of the primary endpoints for the baseline visit and
at least one follow-up visit were available. The last observation
carried forward (LOCF) method was used to replace missing values
for co-primary outcomes as long as there was at least one post-
baseline value available. In case there were no values available from
the immediately following visit, the selection value was used
instead. All other variables were treated using the Available Data
Only (ADO) approach. Primary efﬁcacy variables were also analyzed
in the per-protocol (PP) population to assess the robustness of the
results obtained in the ITT data set. The PP population was deﬁned
as all patients randomized who met the inclusion/exclusion
criteria, received the study medication, and had data from the
primary endpoints for the baseline visit and at least one follow-up
visit and who did not present major protocol deviations. Major
protocol deviations included lack of fulﬁlment of the selection
criteria, non-compliance with the study medication or use of any
systemic or topical medication other than the study drugs or
acetaminophen. The safety population included all randomized
subjects who received at least one dose of the study drug.
Both VAS and PASI were evaluated following an ANCOVA model
with the baseline value as a covariable for each visit. Adjusted
means and their CI 95% bilateral for the mentioned variables (EAV,
PASI and their respective differences frombaseline) were calculated
using ANCOVA. We also performed an additional post-hoc sensi-
tivity analysis of the two co-primary outcomes following Mixed
Models for Repeated Measurements (MMRM) using a restricted
maximum likelihood based approach, including in the model the
ﬁxed, categorical effects of treatment, visit, and treatment-by-visit
interaction, as well as the continuous ﬁxed covariate of baseline.
For all secondary efﬁcacy variables comparability was performed
using Fisher exact test, Student’s t-test and ManneWhitney U-test,
according to the variables nature. When applied, variables were
evaluated similarly as primary variables using an ANCOVA modeltending
isit
Pre-randomisation withdrawals 
Patient’s decision, n = 29
Lack of eligibility, n = 20
Psoriasis flare, n = 3
d, n = 129
Placebo,  n = 65
ITT data set, n = 56
No intake of at least1 dose of study 
medication, n = 1
Safety data set, n = 64
No data for at least one follow-up 
visit, n = 5
No fulfillment of inclusion 
criteria, n = 3
PP data set, n = 51
Non-compliance, n = 3
Use of medication other than 
study drug or paracetamol, n = 2
ibution of study patients.
Table I
Baseline characteristics of the study population (ITT data set)
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set at P 0.05.Data Total patients CS, n¼ 60 PBO, n¼ 56
Sex, male/female 55/61 31/29 24/32
Age, years, mean SD 59.8 10.8 58.6 11.4 61.0 10.4
Weight, kg, mean SD 79.5 16.7 80.3 16.9 78.7 16.7
Family history of psoriasis 25 (21.5) 18 (30) 7 (12.5)
Worsening of lesions with
analgesics/NSAIDs
7 (6.0) 3 (5.0) 4 (7.1)
KellgreneLawrence grade
I 8 (6.9) 4 (6.7) 4 (7.1)
II 87 (75.0) 47 (78.3) 40 (75.0)
III 21 (18.1) 9 (15.0) 12 (21.4)
Pain intensity, VAS score,
mm, mean SD
57.8 16.0 58.1 16.7 56.8 16.0
Lequesne index,* mean SD 9.5 3.5 9.0 6.5 9.9 3.5
PASI score,y mean SD 12.9 5.6 12.8 5.6 12.9 5.7
OLS score,z mean SD 2.7 0.6 2.7 0.6 2.6 0.7
DLQI score,x mean SD 5.3 4.6 5.4 5.0 5.1 4.1
SF-36,{ mean SD
Physical component
summary (PCS-36)
42.9 8.5 44.1 9.1 41.7 7.6
Mental component
summary (MCS-36)
50.4 12.1 50.1 12.1 50.7 12.2
Data as numbers and percentages in parenthesis unless otherwise stated.
* Lequesne indexmeasures pain (ﬁve questions), walking distance (one question),
and activities of daily living (four questions). Scores for each question are added
together to provide a combined disease severity score. Scores of 1e4 are classiﬁed as
mild OA, 5e7moderate, 8e10 severe, 11e13 very severe and 14 as extremely severe.
y The PASI assesses the extent of psoriasis on four body surface areas (head, trunk,
and upper and lower limbs) and the degree of plaque erythema, scaling, andResults
Study population
Of the 181 potential participants, 52 were not enrolled because
of lack of eligibility at the screening visit (n¼ 20), ﬂare of psoriasis
during the washout period (n¼ 3) and patient’s decision (n¼ 29).
Therefore, a total of 129 patients were randomized to the study
arms, 64 of which were assigned to treatment with CS and 65 to
PBO. However, one patient assigned to the PBO group did not take
at least one dose of the study medication and was excluded from
the safety data set. Twelve patients, four in the CS group and eight
in the PBO group, were excluded from the ITT population because
the primary endpoint data was lacking for at least one follow-up
visit (n¼ 9) or because of no fulﬁlment with inclusion criteria
(n¼ 3). In seven other patients, major protocol violations occurred
and were excluded from the PP data set. The disposition of patients
is shown in Fig. 1.
Baseline characteristics were similar among patients in both
groups (Table I). The mean VAS score for the intensity of pain in the
affected knee was 57.8 16.0 mm and the Lequesne index score
was 9.5 3.5. The mean PASI score at baseline for the entire study
cohort was 12.9 5.7. Seven (6%) patients reported a psoriasis
worsening after NSAID consumption (Table I).thickness. The PASI scores account for both the extent of body surface area affected
by the erythema, scaling, and thickness and the severity of these measures. The
score ranges from 0 (no disease) to 72 (maximal disease).
z The OLS is a physician global rating of psoriasis severity at a given point in time
with 6 categories (clear, minimal, mild, moderate, severe, and very severe) based on
the characteristics of plaque elevation, scaling, and erythema.
x The DLQI incorporates patient’s assessments in six subscales scores: symptoms
and feelings, daily activities, leisure, work/school, personal relationships and
treatment. The DLQI scores range from 0 (no impairment) to 30 (maximal
impairment).
{ The SF-36 yields an 8-scale proﬁle of functional health and well-being yielding
information on physical health (comprised of physical functioning, role-physical,
bodily pain, and general health) and mental health (comprised vitality, social
functioning, role-emotional, and mental health). The physical (PCS-36) and the
mental (PCS-36) component summaries can be calculated.Efﬁcacy
Knee OA
Regarding the primary efﬁcacy variable, treatment with CS was
superior toPBO in reducing the intensityofpain throughout the study
period. Absolute differences in VAS scores were statistically signiﬁ-
cant after 1 month of treatment (CS 14.619.5 mm vs PBO
7.217.1 mm, P< 0.05) and at the ﬁnal visit at 3 months (CS
26.9 24.8 mm vs PBO 14.23 20.8 mm, P< 0.01) (Table II,
Fig. 2). The additional post-hoc sensitivity analysis following the
MMRM approach gave similar results conﬁrming the conclusions
obtained with the LOCF analysis (P¼ 0.002).
The administration of CS was associated with a steady improve-
ment in Lequesne index scores over the3-month studyperiod. At the
end of the treatment, absolute differences were statistically signiﬁ-
cant as compared with the PBO group (CS 4.8 3.4 vs PBO
3.3 3.5, P< 0.05) (Table II, Fig. 3). Acetaminophen consumption
was scarce and very similar in both treatment groups. At the end of
the treatment, no statistically signiﬁcant differences were detected
among treatment groups (CS 38.2 42.6 vs PBO 30.2 33.8,
P> 0.05) (Table II). However, at the ﬁnal visit, a signiﬁcantly higher
percentage of PBO-treated patients than CS-treated patients
consumed acetaminophen (CS 43% vs PBO 64%, P< 0.05).
According to the patient’s opinion, the efﬁcacy of CS treat-
ment was rated more favourably than the efﬁcacy of treatment
with PBO, with statistically signiﬁcant differences after 1
(P< 0.05) and 3 months (P< 0.05) of treatment. Efﬁcacy was
considered ‘good’ by 61% of patients in the CS group and 38% of
patient in the PBO group at visit 1, whereas 44% of patients in
the CS group and 20% in the PBO group rated efﬁcacy of treat-
ment as ‘very good’ at visit 3 (Table II). Treatment efﬁcacy was
considered ‘very good’ by 48% of investigators in the case of CS
and by 24% in the case of PBO after 3 months of treatment
(P< 0.05) (Table II). Regarding health-related quality of life,
differences between study groups were observed in the physical
function scale of the SF-36 questionnaire at the ﬁnal visit infavour of CS treatment compared with PBO (mean score CS
85.6 2.19 vs PBO 78.3 2.19, P< 0.05).
Psoriasis
In relation to the primary efﬁcacy variable, CS-treated patients
experienced a reduction of 33% in the PASI after 3 months of
treatment; without achieving statistically signiﬁcant differences as
compared with PBO (Table III). The additional post-hoc sensitivity
analysis following the MMRM approach (P¼ 0.759) conﬁrmed the
results obtained by the predeﬁned LOCF analysis (P¼ 0.842).
There were no signiﬁcant differences in the OLS; although at
months 2 and 3, ‘very severe’ psoriatic lesions were observed in 6%
and 4% of patients in the PBO group and in none of the CS group
(Table III). In the PGA method, although lesions improved in both
study groups, 12% of patients treated with PBO and 2% of patients
treated with CS scored ‘worse’ after the 3-month treatment course
(Table III).
When psoriatic lesions at different body sites were assessed,
a signiﬁcant reduction in the percentage of patients with plantar
psoriasis among those treated with CS compared with PBO was
observed. After the second month of treatment, 33% of patients
treated with PBO had plantar psoriasis as compared with 16% of
patients treated with CS. At the ﬁnal visit, plantar psoriasis was
Table II
Results of efﬁcacy variables for OA of the knee in the CS and PBO arms (ITT data set)
Variable Study period
Baseline 1 month 2 months 3 months
Pain intensity, VAS, mm, mean  SD
CS 58.8  16.7 43.5  2.8 36.5  2.7 31.3  2.8
Placebo 56.8  15.3 50.3  2.4 42.0  2.8 43.2  2.9
Mean difference 6.8 5.5 11.8
95% CI 13.3 to 0.3 13.3 to 2.3 19.9 to 3.7
P value 0.501 0.041 0.165 0.004
Lequesne index, mean  SD
CS 9.0  3.5 7.5  0.3 5.4  0.4 4.5  0.5
Placebo 9.9  3.5 7.3  0.3 6.3  0.4 6.1  0.5
Mean difference 0.19 0.93 1.7
95% CI 0.8 to 1.1 2.1 to 0.2 3.0 to 0.4
P value 0.166 0.700 0.109 0.013
Acetaminophen, number pills/ month, mean  SD
CS 29.5  31.4 32.3  33.9 38.2  42.6
Placebo 29.5  29.6 28.8  28.2 30.2  33.8
Mean difference 3.4 3.9 5.1
95% CI 22.7e36.3 22.6e38.7 23.1e43.7
P value 0.991 0.668 0.453
SF-36 score physical component, mean  SD
CS 44.09  9.1 49.48  7.9
Placebo 41.67  7.7 46.72  8.4
Mean difference 1.7
95% CI 1.4 to 1.2
P value 0.126 0.247
SF-36 score mental component, mean  SD
CS 50.07  12.1 52.83  8.9
Placebo 50.68  12.2 53.42  8.6
Mean difference 0.3
95% CI 3.3 to 2.6
P value 0.789 0.827
Efﬁcacy of treatment,* % of patients
Very good 10.2 vs 10.9 28.1 vs 18.0 44.0 vs 20.0
Good 61.0 vs 38.2 42.1 vs 52.0 36.0 vs 48.0
Mild 27.1 vs 40.0 24.6 vs 22.0 16.0 vs 24.0
Bad 1.7 vs 7.3 3.5 vs 8.0 4.0 vs .8.0
Very bad 0.0 vs 3.6 1.8 vs 0.0 0.0 vs 0.0
P value 0.032 0.458 0.018
Efﬁcacy of treatment,* % of physicians
Very good 11.9 vs 10.9 29.8 vs 28.0 48.0 vs 24.0
Good 67.8 vs 52.7 52.6 vs 46.0 36.0 vs 48.0
Mild 18.6 vs 30.9 12.3 vs 22.0 14.0 vs 28.0
Bad 1.7 vs 5.5 5.3 vs 4.0 2.0 vs 0.0
Very bad 0.0 vs 0.0 0.0 vs 0.0 0.0 vs 0.0
P value 0.109 0.517 0.019
* CS vs PBO.
I. Möller et al. / Osteoarthritis and Cartilage 18 (2010) S32eS40S36present in 22% of patients treated with PBO and in 4% of patients
treated with CS (P< 0.05) (Fig. 4).
Histopathologically, neither biopsies from CS-treated patients nor
biopsies from those treated with PBO showed changes in quantita-
tive, semiquantitative and qualitative histological variables, except
for CD1aþ Langerhans cells, which showed a trend to decrease with
CS treatment (CS 5.13 0.42 vs PBO 6.26 0.43, P¼ 0.06).
Patients rated similarly the efﬁcacy of treatment with CS and
PBO throughout the study period (Table III). In the DQLI, both study
groups showed decreases from baseline to the end of treatment in
the overall score as well as in the six subscales, with a statistically
signiﬁcant difference for the work/school domain in favour of CS
treatment (CS 0.010.06 vs PBO 0.19 0.02, P< 0.05).
The analyses for the PP population supported the results
obtained in ITT patients, as similar results for all efﬁcacy vari-
ables related to knee OA and psoriasis were found in the PP
population.Safety and tolerability
Adverse events were infrequent and evenly distributed
among groups. Adverse events of mild to moderate intensity
were recorded in 31 patients in each group. The most common
adverse events that occurred in both CS and PBO groups were
common cold with a frequency of six and seven cases, respec-
tively; back pain with a frequency of one and ﬁve, respectively;
pruritus with two cases in each treatment group, and dental
pain with a frequency of one and three, respectively. Treatment
tolerability was excellent in both study groups. At the ﬁnal visit,
tolerability of treatment with both CS and PBO was considered
‘very good’ by near 90% of physicians and 80% of patients.
The incidence of psoriatic ﬂares did not increase after
treatments.
No clinically signiﬁcant laboratory abnormalities or pattern
changes in vital signs were observed during CS treatment.
Table III
Results of efﬁcacy variables for psoriatic lesions in the CS and PBO arms (ITT data set)
Variable Study period
Baseline 1 month 2 months 3 months
PASI score, mean SD
CS 12.8 5.7 11.9 0.7 10.1 0.9 8.6 1.0
PBO 12.9 5.7 12.0 0.7 10.0 0.9 8.9 1.0
Mean difference 0.1 0.02 0.3
95% CI 2.1 to 1.9 2.4 to 2.5 3.1 to 2.5
P value 0.893 0.907 0.990 0.842
OLS score, CS vs PBO, % patients
Clear 0.0 vs 0.0 0.0 vs 0.0 1.8 vs 2.0 8.2 vs 10.0
Minimal 0.0 vs 1.9 15.3 vs 14.5 28.1 vs 26.0 36.7 vs 38.0
Mild 38.3 vs 42.9 45.8 vs 41.8 35.1 vs 46.0 36.7 vs 32.0
Moderate 53.3 vs 46.4 25.4 vs 34.5 26.3 vs 16.0 14.3 vs 14.0
Severe 8.3 vs 8.9 11.9 vs 5.5 8.8 vs 4.0 4.1 vs 2.0
Very severe 0.0 vs 0.0 1.7 vs 3.6 0.0 vs 6.0 0.0 vs 4.0
P value 0.532 0.822 0.743 0.878
PGA score,* CS vs PBO, % physicians
Cleared 0.0 vs 0.0 1.8 vs 2.0 2.0 vs 8.0
Excellent 3.4 vs 3.6 12.3 vs 8.2 22.4 vs 18.0
Good 16.9 vs 14.5 21.1 vs 30.6 26.5 vs 32.0
Fair 15.3 vs 20.0 19.3 vs 20.4 14.3 vs 12.0
Slight 15.3 vs 9.1 17.5 vs 10.2 18.4 vs 6.0
Unchanged 28.8 vs 27.3 12.3 vs 8.2 14.3 vs 12.0
Worse 20.3 vs 25.5 15.8 vs 20.4 2.0 vs 12.0
P value 0.713 0.849 0.836
Fig. 2. Average change from baseline of VAS scores during treatment with CS or PBO.
Signiﬁcant differences at 1 month (*P< 0.05) and at the end of the study (3 months)
(**P< 0.01).
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point, with a mean compliance rate of 97%.DLQI overall score, mean SD
CS 5.5 5.0 4.1 4.2 2.8 3.6 2.3 3.1
PBO 5.1 4.1 4.3 3.7 3.1 4.0 2.3 3.2
Mean difference 0.3 0.4 0.01
95% CI 1.7 to 1.0 1.8 to 1.1 1.2 to 1.2
P value 0.705 0.801 0.634 0.981
Efﬁcacy of treatment, CS vs PBO, % of patients
Very good 5.1 vs 7.3 17.5 vs 12.2 20.4 vs 28.0
Good 35.6 vs 38.2 29.8 vs 42.9 30.6 vs 22.0
Mild 33.9 vs 29.1 35.1 vs 26.5 34.7 vs 26.0
Bad 23.7 vs 20.0 15.8 vs 16.3 14.3 vs 24.0
Very bad 1.7 vs 1.5 1.8 vs 2.0 0.0 vs 0.0
P value 0.758 0.853 0.894
* The PGA corresponds to the physician’s global assessment of changes in all
psoriatic lesions compared to the baseline condition (using photographs from
baseline to aid in making the assessment). The possible scores are “cleared” (100%
improvement); “excellent” (75%e99% improvement); “good” (50%e74% improve-
ment); “fair” (25%e49% improvement); “slight” (1%e24% improvement);
“unchanged”; and “worse”.Discussion
This randomized, double-blind, PBO -controlled study presents
the results of a 3-month clinical trial conducted in patients with
knee OA and concomitant psoriasis receiving oral CS, 800 mg on
a daily basis.
Although multiple controlled trials since the 1980s have
examined the use of oral CS in patients with symptomatic OA of the
knee, the beneﬁts in terms of pain reduction, improvement of
functional disability and decrease in NSAID consumption are still
debated3.
The results of this study, designed to assess the clinical effects of
CS on pain amongst other outcomes, conﬁrm previous positive
results obtained with CS used for the symptomatic treatment of
human OA3,5,7,9,10,27e30. In this clinical trial CS elicited a signiﬁcant
reduction of pain intensity as compared with PBO after the ﬁrst
monthof treatment, providing further evidence forCS as a SYSADOA.
The effect of CS increased progressively over time, achievingFig. 3. Average changes of Lequesne score during treatment with CS or PBO. Signiﬁcant
differences at the end of the study (3 months) (*P< 0.05).a maximal effect after 3 months of treatment. The results from the
secondary efﬁcacy parameters in OA conﬁrmed the effect of CS with
statistical signiﬁcance at several endpoints. A signiﬁcantly higher
increase in physical function than in the PBO armwas also observed
after 3 months of treatment with CS. The global assessment by the
investigators and patients was also signiﬁcantly better in the CS
group.
In agreement with the effect of CS on pain and function, CS was
also able to improve the patient’s health-related quality of life
according to the SF-36 questionnaire. This ﬁnding is relevant for
clinical practice as knee OA has been described to have one of the
worst quality of life patterns among musculoskeletal disorders31.
With reference to psoriasis, CS did not reach statistically
signiﬁcant results in the primary outcome together with OLS and
PGA. However, it is noteworthy that CS at dose of 800 mg/day
demonstrated a statistically signiﬁcant improvement of plantar
psoriasis. At the end of treatment, only 2% of patients in the CS
group complained of plantar psoriasis compared with 22% of those
treated with PBO. Palmoplantar psoriasis is one of the most inva-
lidating forms of psoriasis that impacts activities of daily living32
and affects the hands or feet (or both) with very dry, thickened
skin, ﬁne desquamation, often involving splitting and cracking and
a silvery appearance.
AB
Fig. 4. (A) Percentage of patients with plantar psoriasis during treatment with CS or PBO. Signiﬁcant differences at the end of the study (3 months) (*P< 0.05). (B) Reduction of
plantar psoriasis intensity over the 12-week treatment period with CS 800 mg/day. (i) Before treatment, (ii) After treatment.
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greater physical disability and physical discomfort than patients
without palmoplantar involvement32. In this clinical trial and in
accordance with the former results, the substantial clinical
response to treatment was correlated with an improvement of
patient’s quality of life according to DLQI.
It is worthmentioning that psoriasis is a diseasewith evident NF-
kB activation33. The deregulation of NF-kB appears to play an
important role in skin inﬂammatory processes, such as psoriasis18.
The nuclear expression of NF-kB is detected in 66% of psoriatic
lesions and over-expressed in psoriasis compared with normal
skin34. Moreover, the NF-kB-dependent proinﬂammatory cytokines,
IL-1b and TNF-a, have a crucial role in the appearance and
progression of psoriasis and psoriatic arthritis35,36. Further sup-
porting the role of NF-kB in psoriasis are the reports showing that
effective treatment of psoriasis diminishes NF-kB nuclear trans-
location. For instance, one study showed that etanercept produced
a signiﬁcant down-regulation of phosphorylated NF-kB/RelA effect
that correlated with decreases in epidermal thickness, restoration of
normal markers of keratinocyte differentiation, and clinical
outcomes37. Furthermore, the anti-psoriatic effect of avarol-30-
thiosalicylate38, dimethyl fumarate39 and tacrolimus40 is closely
associated to the down-regulation of NF-kB activity. Recent studies
have reported that CS is able to inhibit the nuclear translocation of
NF-kB in chondrocytes15 and synoviocytes16 and therefore, to
explain CS in some patients with psoriasis, we may postulate that CS
may also reduce nuclear translocation of NF-kB in psoriatic skin cells.
The therapeutic efﬁcacy of CS may have implications in clinical
practice since palmoplantar psoriasis is usually resistant to most of
the available therapeutic modalities41. Results of this clinical trial
are encouraging and warrant further studies in patients with
psoriasis to assess the effects of CS treatment for a longer period of
time.Current therapies for psoriasis are limited, therefore there is
a need for effective and safe treatment options42. The need for
alternative therapies is reinforced by the demographic change in
age distribution that will lead to more elderly people with psoriasis
with an increasing number of coexisting conditions43, and so it may
be expected that a large percentage of patients with psoriasis will
suffer from OA in adulthood. Moreover, the need for new thera-
peutic approaches to treat patients with both pathologies is further
emphasized by the fact that some anti-inﬂammatory medications,
commonly used in the management of OA are considered potential
risk factors for psoriasis, in particular, propionic acid derivatives44,
as NSAIDs may induce psoriasis ﬂares or aggravate preexisting
lesions44e51. The data available on the beneﬁcial effect of CS in
psoriasis19,20 and the results observed in the present clinical trial
suggest that CS could represent a therapeutic alternative for many
patients.
In conclusion, the daily administration of 800 mg/day of CS for 3
months improved OA-associated pain, physical function, and
plantar psoriasis, and enhanced quality of life of patients with OA
and psoriasis.
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